David Johnson of Gigagen

David S. Johnson, PhD, MBA

Chief Executive Officer and Co-Founder

Dr. Johnson is an inventor, entrepreneur, and expert in single-cell genomics with a track record of bringing new medical technologies to market. Dr. Johnson was among the founding members and COO of Natera, a Silicon Valley genetics startup funded by Sequoia Capital and other top-tier venture capitalists. At Natera, Dr. Johnson was responsible for all clinical operations, laboratory research, clinical studies, and clinical product development. He was directly responsible for invention and commercialization of two genomic products for preimplantation genetic diagnosis (PGD), which captured >30% market share less than a year after commercial launch. Prior to Natera he was the ENCODE Project Director at the Stanford Human Genome Center. Dr. Johnson holds a BS in Biology from Duke University, a PhD in Genetics from Stanford University, and an MBA from the Haas School of Business at the University of California, Berkeley.

Carter Keller at SRK Headshot Day

Carter Keller

Chief Operating Officer

Mr. Keller is a health care executive with over 15 years of experience developing and commercializing biopharmaceutical therapeutics with specific expertise in antibody therapies. Prior to joining GigaGen he was Senior Director of Marketing at Exelixis where he led the EU and US commercial launch of cabozantinib into an orphan oncology indication. Preceding Exelixis he held a variety of senior marketing, commercial planning, and strategy roles at Achaogen, Genentech, and APM/CSC Healthcare. Mr. Keller holds a BSE in Chemical Engineering from Stanford University and an MBA from The Haas School of Business at the University of California, Berkeley.


Everett Meyer, MD, PhD

Co-Founder and Medical Advisor


Dr. Meyer is an Assistant Professor of Medicine at Stanford University Medical School and Co-Founder of GigaGen with research expertise in immune profiling and immunotherapeutics. Dr. Meyer's research focus has included the role of T-cell populations in immune dysregulation, specifically through the mechanistic study of how CD1d-restricted invariant NKT mediate allergy and asthma in both mouse models and human clinical samples. He is the author of over 20 publications in leading journals and holds a BS from Yale, an MS in Molecular Evolution from Stanford University, and a combined MD/PhD degree training at Stanford Medical School.

Adam Adler of Gigagen

Adam Adler, PhD

Vice President of Research and Development

Dr. Adler has over ten years of research and laboratory management experience including deep expertise in antibody sequencing. At GigaGen he manages laboratory research operations and is responsible for sequencing millions of B-cells every hour. Prior to GigaGen Dr. Adler held research management roles at Lake Pharma where he was responsible for all internal and external projects including developing new antibody sequence analysis tools, and at Genentech where he worked to identify novel oncogenes and validate cancer drug targets. Dr. Adler has authored over 20 research publications in leading journals and holds a BA in Biology from Northwestern University and a PhD in Cancer Biology from Stanford University.


Rena Mizrahi, PhD

Director, Protein Engineering

Dr. Mizrahi has deep expertise in synthetic biology and RNA editing mechanisms, and leads antibody expression research and development at GigaGen. Prior to GigaGen she held research positions at Genentech, DuPont Industrial Biosciences (Genencor), and Lawrence Berkeley National Laboratory. Dr. Mizrahi holds a BS in Chemistry from Washington University in St. Louis and a PhD in Chemistry with a Designated Emphasis in Biotechnology from the University of California, Davis, where she was also a National Science Foundation Graduate Research Fellow. 

Matt Spindler of Gigagen

Matthew Spindler, PhD

Director, Cell Engineering

Dr. Spindler is a biomedical scientist and entrepreneur with strong experimental biology and genomics expertise. He has extensive experience studying human disease using high-throughput molecular, cellular, and in vivo biology with specific expertise in genome-editing and checkpoint inhibitor research. Dr. Spindler has also worked closely with multiple San Francisco Bay Area museums, including the Exploratorium and California Academy of Sciences, to help educate and promote scientific research to the public.  Dr. Spindler holds a BS in Genetics from the University of Wisconsin and a PhD in Pharmaceutical Sciences and Pharmacogenomics from UCSF.

J Keller_121914_0048-2_cropped

Jennifer Keller, MS, MBA

Head of Marketing

Ms. Keller (no relation to Carter Keller) has over 15 years of experience in human genetics, healthcare delivery, and medical marketing. Prior to joining GigaGen she was one of the founding executive members of Natera, where she held positions as Vice President of Marketing and Vice President of Medical Education leading the launch and growth of several diagnostic products. Preceding Natera, she served in a variety of managerial and marketing roles at Cord Blood Registry, Genentech, and Kaiser Permanente. Ms. Keller is a Certified Genetic Counselor through the American Board of Genetic Counseling and holds a BS in Biology from San Francisco State University, an MS in Health and Medical Sciences from the University of California at Berkeley, and an MBA from the University of California, Irvine.


Robert Edgar, PhD

Senior Scientist, Head of Bioinformatics 

Dr. Edgar is a scientist and entrepreneur with more than 30 years of experience in developing high-throughput algorithms for analysis of next generation sequence data and high performance software. In the field of computational biology, he is best known for developing the multiple alignment algorithm MUSCLE, which is one of the most highly cited methods in biology with 12,099 citations to date (Google scholar retrieved 1/7/2015). Prior to GigaGen Dr. Edgar was CEO and Founder of Parity Software which was bought by Intel in 1999, and CTO at IDBS. Dr. Edgar holds a BSc in Physics with 1st Class Honors and a PhD in Particle Physics from the University College of London.


Steve Chamow, PhD


Dr. Chamow has more than 20 years of experience in biopharmaceutical manufacturing process development. Previously, he served as Senior Vice President, CMC, at Intradigm Corporation, a private biopharmaceutical company focused on developing RNAi therapeutics (acquired by Silence Therapeutics). Prior to Intradigm, Dr. Chamow was Vice President, Process Sciences, at Genitope Corporation and at Abgenix, Inc., (acquired by Amgen) where he built the company's process sciences department and co-led the design and construction of Abgenix' award-winning mammalian cell production facility in Fremont, CA. Dr. Chamow is author or co-author of more than 45 scientific publications and patents and co-editor of a 1999 book entitled Antibody Fusion Proteins.


Mark Robbins, PhD, JD

Regulatory Advisor

Dr. Robbins is a bio-pharmaceutical drug development professional with over 30 years of broad-based drug development and commercialization experience. Dr. Robbins has overseen development and successfully implemented regulatory/clinical strategies leading to many successful NDA/BLA approvals.  He is past Chair of the Food and Drug Law section of the MN State Bar Association and taught Food and Drug law at a number of law schools. Dr. Robbins holds a BS degree in Biochemistry from UCLA, a PhD in Pharmacology from the University of Minnesota Medical School, and a JD magna cum laude from St. Louis University.

Board of Directors


Charles "Chuck" Wilson, PhD

Independent Director

Dr. Wilson is the CEO and Co-Founder of Unum Therapeutics, an antibody therapeutics company discovering new cellular immunotherapies for cancer using Antibody-Coupled T-cell Receptor (ACTR) technology. Before founding Unum, he held a number of scientific and business management roles in biotechnology, most recently as Senior VP for Corporate Development at Novartis, where he led partnering efforts and was responsible for all efforts in drug discovery up through clinical Phase II development. He has in-depth deal experience in biotech and academic collaborations, product in-licensing, spin-outs, and strategic equity investing in early stage companies.